Ana Tomas-Alarcon

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy.

Managing cytokine release syndrome in hematological malignancies being treated with CAR-T cell therapy.

Journal: Expert review of hematology

Published: June 03, 2026

Antibody Titers of Vaccine-Preventable Pathogens at 1 Year Post CD19 CAR-T Cell Therapy.

Antibody Titers of Vaccine-Preventable Pathogens at 1 Year Post CD19 CAR-T Cell Therapy.

Journal: Transplantation and cellular therapy

Published: July 15, 2025

CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.

CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.

Journal: Blood cancer journal

Published: December 24, 2024

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.

Journal: Bone marrow transplantation

Published: September 05, 2024

CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.

CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.

Journal: Blood advances

Published: April 15, 2024

Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.

Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 14, 2024

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.

An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.

Journal: Nature medicine

Published: July 07, 2023

Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.

Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.

Journal: Expert opinion on drug safety

Published: February 03, 2023

Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.

Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.

Journal: Leukemia

Published: July 03, 2022

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 03, 2021

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.

Journal: Blood advances

Published: November 23, 2020

The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant.

The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant.

Journal: Bone marrow transplantation

Published: September 24, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026